News
1d
Zacks Investment Research on MSNHere's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
1d
Zacks Investment Research on MSNCatalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue?It has been about a month since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have added about 11.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more ...
Below, we take a look at Catalyst Pharmaceutical (CPRX), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the ...
CPRX has been the topic of a number of research reports. Robert W. Baird boosted their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform ...
This was the stock's second consecutive day of gains.
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results